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A copious amount of scientiic scrutiny has been dedicated to documenting typical and atypical human ageing, with a substantial
body of work focusing upon the impact of lifestyle choices. One such lifestyle choice is that of diet and, in particular, micronutrient
ingestion. Epidemiological studies have reported positive associations between B vitamin status and cognitive function, including
negative associations between biological markers (i.e., homocysteine) of dysregulated one-carbon metabolism and cognitive
function. his has led to a surge of randomised control trials (RCTs) investigations into B vitamin therapy. However, results
have continuingly failed to show beneicial behavioural efects. Despite this, results reliably show treatment-related increases in
B vitamin level and decreases in homocysteine level—both of which have been identiied as risk factors for atypical ageing. In
this paper we argue that it would be premature to conclude that B vitamin therapy has no potential and that more research is
needed to systematically investigate the optimal dose, the therapeutic “window,” and individual diferences in therapy responders
and nonresponders. We start with a brief look at one-carbon metabolism and then consider the evidence from epidemiological
studies and RCTs in relation to three speciic B vitamins: folic acid (B9), pyridoxine (B6), and cobamides (B12).
1. Mechanism of Action
In 1992, two papers suggested that elevated levels of
homocysteine may be a biological marker of abnormal one-
carbon metabolism and that this may play a role in the
aetiology of Alzheimer’s disease (AD) [1, 2]. Behavioural
support for this hypothesis comes from epidemiological work
in healthy adults and patient populations, which demon-
strates a negative association between homocysteine levels
and cognitive function. In addition, it has been reported that
elevated homocysteine levels are an independent risk factor
for AD (see [3]).
One-carbon metabolism refers to the generation
of one-carbon units, normally from serine, through
association with a folic acid derivative; tetrahydrofolate
(THF), to form 5, 10-methylenetetrahydrofolate and then
5-methyltetrahydrofolate. his, in turn, is used to methylate
homocysteine, in a reaction catalysed by B12, and is used
in the synthesis of methionine. Smith [3] outlines twelve
biologically plausible mechanisms to explain the association
between B vitamins, homocysteine, and dementia. However,
Selhub et al. [4] state that the evidence for such mechanisms
relies on animal and cell culture models and that there
is “no supportive evidence to suggest the concentrations
of homocysteine in brain or CSF reach levels considered
neurotoxic, based on in vitro data” ([5]; page 115).
2. Epidemiological Evidence
he relationship between B vitamin status and cognitive
function gained momentum when reports began reporting
associations between B vitamin status and cognitive function
in the elderly. Such evidence is derived primarily from
epidemiological studies.
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2.1. Healthy Elderly. Goodwin et al. [6] were the irst to link
nutritional status (using food record diaries and blood levels)
and cognitive function in the healthy elderly population
(mean age 71 years; � = 260). Essentially, Goodwin and
colleagues used three diferent analyses to investigate this
link: irst, simple correlations were made between nutri-
ent blood levels (protein, ascorbate, thiamine, ribolavin,
pyridoxine, B12, niacin, and folate) and cognitive function
(Russell revision of the Wechsler Memory test; Halstead-
Reitan Categories Test). Using blood levels, the authors
reported signiicant correlations between nutritional status
and cognitive function for two nutrients (ribolavin B2 and
ascorbate vitamin C) which could account for 2-3% of
the variance in cognitive function. Using the participant’s
nutritional status they then extracted the bottom 5% and
10% of the sample and compared their blood nutrient levels
to those of the rest of the sample (i.e., 90–95% of the
participants). Based on variance in levels of ascorbate and
B12 vitamins, there was a signiicant group diference on the
Russell revision of the Wechsler Memory test. Following this
irst identiication of a possible link between these nutritional
factors and cognitive function, subsequent associations have
been reported regarding the involvement of vitamin B in age-
related cognitive decline (for a review see [7]).
One issue that has hindered the evaluation of the link
between vitamin B intake and cognitive function is the fact
that low B vitamin levels and high homocysteine (Hcy) levels
are generally concomitant. Further research has attempted to
investigate the relative importance of each of the B vitamins
and Hcy for successful cognitive function. Riggs et al. [8]
investigated the relationship between Hcy, B6, B9, and B12
with cognitive function in 70 males (mean age 66 years)
as part of a normative aging study. he indings of this
study revealed that lower concentrations of B9 and B12 and
higher concentration of Hcy were associated with reduced
spatial copying skills. Importantly, however, Hcy provided
the strongest predictor of performance. In addition to this,
results revealed higher concentrations of B6 to be related to
better memory performance, leading the authors to suggest
that the diferent B vitamins and Hcy may have diferential
efects upon diferent cognitive processes. An interesting
observation from this study was that these associations were
observed despite few participants having clinically relevant
low vitamin B12 (<200 ng/L) and B9 (<3�g/L) levels.
In similar research, Tucker et al. [9] used data from
the Veterans Afairs Normative Ageing Study (NAS) to
investigate associations between Hcy, B6, B9, and B12 with
cognitive decline in 321 men (mean age 67 yrs; mean Mini-
Mental State Exam—MMSE 27.2) over a 3-year period. In
line with the results of Riggs et al. [8], Tucker and col-
leagues reported that higher concentrations of B9 (folate)
and B12 and lower concentrations of Hcy were associated
with better spatial copying skills. hey also note B9 as being
particularly relevant with regard to cognitive decline since
an association was also found with the cognitive measure
of verbal luency. However, when considering the relative
importance of the diferent vitamins on diferent components
of cognition, Tucker et al. [9] reported vitamin B9 to be
the only predictor of performance once the contribution of
other vitamins was controlled for through covariance. In
extending their research, Tucker and colleagues reported that
only when vitamin B9 levels drop to <20 nmol/L is there a
signiicant loss of spatial copying ability. Taken together this
study demonstrated that folate may be particularly useful
in protecting against cognitive decline, measured by spatial
copying and language luency tasks.
he diferential impact of B vitamins on components of
cognition has further been emphasised by Feng et al. [10],
who investigated the relative associations between cognitive
function and vitamins B9 and B12 and Hcy levels in 451 high-
functioning elderly (>55 yr old) Chinese adult volunteers
from the Singapore Longitudinal Ageing Study (MMSE ≥
24). In this study, higher levels of Hcy were associated with
poorer performance on the Block Design task (a measure of
visuospatial motor skill) and the Symbol Digit Modality Test
(a measure of executive functioning). Further, higher levels
of vitamin B9 were associated with better performance of
the Rey Auditory Verbal Learning Test and verbal luency,
and, inally, levels of vitamin B12 were not associated with
performance on any of the cognitive tasks.
It is worth mentioning one study that investigated these
associations across a broader age group, rather than restrict-
ing the sample to older adults. Using a sample of 2,871
participants from the Northern Manhattan Study, Wright et
al. [11] reported an association between higher Hcy levels and
lower mean MMSE scores for adults older than 65 years but
not for adults between the ages of 40 and 64 years. Adjusting
for B12 deiciency and sociodemographic factors, the mean
MMSE was 2.2 points lower for each unit of increase in the
log Hcy level.
On the basis of the studies summarised in this section,
it is apparent that clear associations have been established
between B vitamin levels, as well as Hcy levels, and cognitive
function in older healthy adults. here are also suggestions
of independent and diferential efects of some B vitamins
on subcomponents of cognitive processing; however, it is
clear that further research is needed to fully understand
these associations with regard to process-speciic efects and
“critical” levels.
he next section will consider evidence of a relationship
between B vitamin status and the risk of developing Mild
Cognitive Impairment (MCI) and Dementia.
3. MCI and Dementia
he chance of developingMCI and/or dementia in later life is
exacerbated by a number of risk factors. Although the biggest
risk is increased age, there is substantial research investigating
risk factors associated with lifestyle choices, one of these
being nutritional deiciencies. Droller and Dossett [12] irst
reported a link between low vitamin B12 level and dementia
that was independent of pernicious anaemia (B12 deiciency
anaemia). Subsequent to this, other studies have attempted to
establish the relative importance of each B vitamin andHcy as
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risk factors for developing MCI and dementia. For example,
Quadri et al. [13] examined associations between plasma
Hcy, B9, and B12 and the probability of developing MCI,
dementia of the Alzheimer’s type (AD), or vascular dementia
(VaD). Quadri and colleagues categorised 228 participants
into 3 groups: an elderly control group (� = 55, mean
age 76 years); those diagnosed with MCI (� = 81, mean
age 76 years); and those diagnosed with dementia (� =
92, mean age 80 years). Results revealed that vitamin B9
concentrations were lower in the dementia groups and MCI
group compared to those of the control group. Hcy was
also higher in the dementia groups in comparison to that
of the elderly control group, and the proportion of people
in the dementia groups with higher than normal Hcy level
(<14.6 �mol/L) was greater, in comparison to that of the
control group. he sample was further subcategorised using
tertiary split, and odds ratios were calculated. Results suggest
that those with the highest Hcy levels (>14.6 �mol/L) and the
lowest B9 levels (<13.5 nmol/L) were more than 3 times more
likely to develop AD.his is in line with Tucker et al. [9], who
also report “critical” values of B9 levels belowwhich cognitive
impairment is typically observed, albeit in a diferent value
and in a nondemented population.
In further research, Ramos et al. [14] utilised the Sacra-
mento Area Latino Study on Aging (SALSA) to investigate
the relationship between vitamin B9 status, cognitive func-
tion, and dementia diagnosis in 1789 community-dwelling
individuals of Latino ethnic background over 60 years of age.
Employing a 4-stage regression analysis, results revealed that
B9 status was correlated with performance on all 7 cognitive
tasks (model 1) and was correlated with 6 cognitive tasks ater
Hcy (model 2), and vitamin B12 and creatinine (model 3)
were controlled for statistically. However, when demographic
variables and depression scores were added (model 4), vita-
min B9 only correlated with 3MSE (a measure of global cog-
nitive ability) and delayedmemory recall. Secondary analyses
demonstrated that the odds ratios (OR) (controlling for Hcy,
B12, creatinine, demographic variables, and depression score)
for (i) low 3MSE score (<78) and (ii) dementia diagnosis
decreased with increasing B9 concentrations. he OR for
Hcy did not remain signiicant ater controlling for vitamin
B9. In addition, Haan et al. [15] investigated the relationship
between Hcy, vitamin B9, and vitamin B12 and the risk
of developing dementia or cognitive impairment without
dementia (CIND) in 1405 participants aged 60–101 years old.
In contrast to Ramos et al. [14], Hann et al. reported that
it is Hcy (not B9) that is associated with a greater risk of
dementia or CIND and that higher B12 concentrations may
reduce this risk. To further complicate matters, Mooijaart et
al. [16] also investigated the relationship between (i) Hcy, (ii)
B12, and (iii) B9 and cognitive decline. Five hundred and
ninety-nine elderly participants completed a test battery at 85
years of age and yearly thereater until they were 89 years of
age. Hcy, vitamin B12, and B9 were measured at the irst (i.e.,
85 years) and the last (i.e., 89 years) testing sessions. A cross-
sectional analysis at 85 years showed a negative relationship
between Hcy and MMSE, a positive association between
B9 and cognitive function, but no signiicant relationship
between B12 and cognitive function. A prospective analysis
showed that concentrations of Hcy, vitamin B12, and B9 at 85
years were not predictive of cognitive decline over the study
period.However, it should be noted that participantswere not
screened for health or demographic variables (shown to be
important by Ramos et al. [14]). It is diicult to reconcile such
opposing results. However, some of the conlicting results
may be due to diferent methods and the populations being
studied.
One potentially important methodological confound
between studies in this area is the method used to measure
vitamin B status. his potential conlict is highlighted by the
results of Clarke et al. [17] who investigated the associations
between cognitive decline and levels of vitamins B12, B9,
and Hcy (measuring holoTC, tHcy, MMA, and vitamins
B12 and B9 levels). Cognitive function was assessed in 1648
participants at baseline (mean age 75 years; mean MMSE
26.2) and again at a minimum of 3 time points over a 10-year
period. Six hundred and ninety-one participants survived
until the 10-year followup (mean age = 72 years; meanMMSE
= 27.3). Cross-sectional analyses at baseline and at the 10-year
followup revealed signiicant associations between several
factors, for example, between tHcy and cognitive function,
between holoTC (a marker of reduced vitamin B12 status)
and cognitive function, and between MMA and cognitive
function. Longitudinal analyses revealed that a doubling in
holoTC concentrations (50–100 pmol/L) was associated with
a 30% slower rate of cognitive decline. Conversely, a doubling
in tHcy (from 10 to 20 �mol/L) or MMA (0.25 �mol/L)
was associated with >50% more rapid cognitive decline.
Interestingly, in contrast to the previous studies, Clarke and
colleagues found no association between cognitive function,
total vitamins B12 or B9 levels.he authors suggest these may
be less accurate markers of B vitamin status in comparison
to holoTC and MMA. An additional consideration is that
there is evidence to suggest that the relationship between
vitamin B12 status and cognitive function in older individuals
may be moderated by APOE (Apolipoprotein E). Feng et al.
[18] investigated this possibility. Five hundred and thirty-
nine adults (mean age 65 years) completed a number of
cognitive function tests including theMMSE.heMMSEwas
completed at baseline (all participants had had an MMSE
>21) and ∼18 months and ∼38 months thereater. Results
suggest that the relationship between B12 and MMSE score
was stronger in the carriers of the APOE �4 (the dysfunc-
tional isoform) than noncarriers, suggesting that APOE �4
moderates this relationship. However, it should be noted that
this moderating efect was not present when the relationship
was analysed in a subsample of 416 “cognitively normal” (i.e.,
nondemented) adults.
It is clear from extant indings that Hcy levels and vitamin
B status are related to MCI and dementia in the elderly.
However, to date the nature of the relative contribution of
each of the B vitamins and Hcy is not fully understood.
In addition to this, there is evidence of “critical” levels and
individual diferences in vulnerability that deserve further
research.
As a result of these associations, a substantial research
has now been conducted to ascertain whether B vitamin
supplementation can slow age-related cognitive decline. he
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next section will discuss some of the empirical studies that
have addressed this research question.
4. Vitamin B Supplementation Studies
here has been substantial research conducted to date which
has investigated whether B vitamin supplementation can aid
cognitive function in the elderly.hemajority of the evidence
obtained using experimental methodology has provided no
evidence of eicacy of vitamin B supplementation. However,
it is clear that more research is needed to answer a number
of fundamental questions related to any treatment: (1) what is
the optimal dose required; (2) what is the optimal treatment
period; (3) is there a therapeutic window; and (4) what are the
individual diferences in responders and nonresponders. To
date, these questions have not been suiciently investigated
or satisfactorily answered. In addition to this, research needs
to further explore the interaction between approved medical
treatments for dementia and nutritional supplements whilst
controlling for important extraneous variables (e.g., genetic
and demographic variables).
One of the main problems with research in this domain
has been methodological. For example, Yukawa et al. [19]
assessed the efects of 60-day treatment with vitamin B9
(15mg per day) in 36 (mean age 56 years old) vitamin B9
deicient volunteers (deined as <4 ng/mL serum folate), all
with neurological disease. Results suggested that B9 adminis-
tration improved neurological symptoms in 24 of the 36 cases
ater 2 months (8 of these individuals have been diagnosed
with dementia). However, Yukawa et al. did not include a
placebo control group in their study. Similarly, Nilsson et
al. [20] investigated the efects of an oral supplementation
of vitamins B12 (1mg day) and B9 (5mg/day) for 2 months.
hirty-three patients (mean age 78 years) were classiied with
mild, moderate, or severe dementia (categorized according
to DSM III-R criteria). he patients with severe dementia
were too ill to participate and were excluded from this study.
he remaining 28 patients were subcategorised into two
groups based on their Hcy levels (those having a plasma Hcy
level <19.9 �mol/L and those above). Results revealed that
the patients with high Hcy (>19.9 �mol/L) showed clinical
improvements ater oral supplementation of vitamin B12.
However, once again the study failed to implement a placebo
control group.
In studies that have used more rigorous methods, the
results aremuch clearer.he conclusions obtained from these
scientiic investigations indicate that vitamin B supplemen-
tation has no efect upon cognitive function alone or in
combination (for reviews, see [21–23]). However, it should be
noted that individual studies have varied substantially with
regard to treatment, treatment dose, duration of treatment
regime, study population, and method of assessment of
cognitive function. In addition, some studies have used a very
small sample size, which inevitably increases the probability
of reporting indings that support a null hypothesis, due
to decreased power. Some of the relevant problems will be
highlighted in the remainder of this paper, where we will
consider the evidence of monotherapy and multivitamin
therapy.
5. Monotherapy with Vitamins
B6, B9, and B12
he majority of monotherapy studies have elected to study
vitamin B9 and have kept the experimental design simple
(something that we would advocate) by comparing one B
vitamin with placebo. However, one study has investigated
the efect of B6, B9, and B12 against a placebo. Bryan et al.
[24] utilised a placebo-controlled design to investigate the
efect of 35 days of B vitamin supplementation on cognitive
function and mood in three age ranges: (1) young adults
(20–30 years old, � = 56), (2) middle-aged adults (45–55
years old, � = 80), and (3) older adults (65–92 years old,
� = 75). Participants were randomly allocated to one of 4
treatment conditions (1) B9 (0.75mg), (2) B12 (0.015mg), (3)
B6 (75mg), or (4) placebo. Results revealed no signiicant
evidence of a treatment efect on cognitive function and no
signiicant efect on subjective mood.
6. Vitamin B6
Few studies have investigated the therapeutic value of vitamin
B6 as a monotherapy. Deijen et al. [25] utilised a placebo-
controlled trial investigating the efects of 12 weeks of daily
ingestion of vitamin B6 (20mg). Seventy-six healthy vol-
unteers (mean age 73 years) were assigned to treatment or
placebo groups using a matched pairs methodology. Twelve
participants in the placebo condition and 4 participants in the
treatment condition were deined as marginally B6 deicient
at baseline (PLP <20 nmol/L or �-EAST >1.98). However,
these participants were retained in the study, thereby raising
some doubts about the match pairing methods used (par-
ticipants were reportedly matched on age, B6 status, and
IQ). Results provided minimal support for a treatment efect,
using multiple bivariate correlations to examine changes in
cognitive performance and PLP baseline levels. Although
the authors did report some signiicant efects, they failed
to control for multiple comparisons and did not report the
associations obtained in the placebo group.
7. Vitamin B9
Numerous studies have investigated the therapeutic value of
vitamin B9 folate as a monotherapy. However, the disparity
in methods makes it almost impossible to form a rational
conclusion, other than one that requests more research to be
carried out. Pathansali et al. [26] utilised a placebo-controlled
design to investigate the efect of daily ingestion of vitamin
B9 (5mg) over a 4-week period on cognitive function in 24
healthy older adults (mean age 73 years; MMSE >27) with
normal baseline B9 levels (6.3 ± 2.4 �g/L). Results demon-
strated no efect of vitamin B9 on psychomotor function.
B9 levels increased following treatment, and Hcy levels were
reduced. Over a longer treatment period and implementing a
larger dose, Sommer et al. [27] utilised a placebo-controlled
ISRN Nutrition 5
design to investigate the efects of daily vitamin B9 treatment
(10mg) over a 10-week supplementation period in 7 patients
(mean age 77 years old) sufering from dementia (classiied
by DSM-III-R) who also presented low vitamin B9 levels
(deined as serum B9 between 2 and 5mcg/L or RBC B9
between 127 and 452mcg/L and B12 above 200 ng/L). Results
show no efect of B9 supplementation in comparison with
placebo. Connelly et al. [28] investigated a longer treatment
period but reduced the daily dose. In a placebo-controlled
trial, these researchers investigated the efect of vitamin B9
treatment on 41 (mean 76 years; mean MMSE 23.49) par-
ticipants with probable AD (meeting the NINCDS-ADRDA
diagnostic criteria). Participants were allocated to daily treat-
ment (1mg of B9) or placebo for 6 months. At the same
time, all participants started cholinesterase inhibition (ChI)
treatment. However, the type of ChI and dose varied across
participants, depending on their clinical response. Results
show that 23 out of 28 participants in the folic acid groups and
7 out of 18 participants in the placebo group were classiied as
NICE (National Institute for Health and Clinical Excellence)
responders (deined as having good response ater 6 months
treatment, according to NICE criteria; NICE 2001). Within
group change from baseline showed improvements following
B9 on activities of daily living and social behaviours but
no change in MMSE score. However, it is very diicult
to delineate the efects of ChI in this study (and possible
interaction with B9 supplementation), given the personalised
medical treatment.
In a large study, Durga et al. [29] implemented a placebo-
controlled, between-subjects design to investigate the efects
of daily B9 supplementation (0.8mg of B9) for 3 years on
cognitive function in 818 individuals (mean age 60 years:
MMSE at baseline >24). Four hundred and four participants
were allocated to the intervention group. Within group
comparisons of change data revealed better cognitive perfor-
mance following B9 treatment. However, as with Connelly
et al. [28], within group comparisons were not supported by
between group diferences, and the results should therefore
be treated with some caution.
8. Vitamin B12
In a very small study, Seal et al. [30] utilised a placebo-
controlled design to investigate the efects of two doses of
vitamin B12 (0.01mg or 0.05mg) ingested daily for 1 month
by 31 older adults (mean 81.4 years; mean MMSE 18.23)
with subnormal vitamin B12 levels (serum B12 between 100–
150 pmol/L). Results revealed that 0.05mgB12 daily increased
serum B12 but did not afect cognitive function. In a larger
study conducted over a longer period of time and using a
larger dose, Hvas et al. [31] utilised a placebo-controlled trial
to investigate the efect of 3-month treatment with vitamin
B12 (1mg intravenous). One-hundred and forty participants
(mean age 74.5 years; mean MMSE = 26.5) were randomly
assigned to either treatment or placebo groups. Participants
had increased P-MMA (0.4–2 �mol/L) and high tHcy (mean:
13 �mol/L) at baseline. Results revealed no signiicant efect
of treatment on cognitive performance.
9. Multi-B-Vitamin Therapy
A number of studies have investigated the efect of B vitamin
treatment in combination with two or more B vitamins.
Stott et al. [32] implemented a placebo-controlled trial to
investigate the efect of a 12-week vitamin supplementation
programme on Hcy levels (assessed at baseline and 3 months
later) and cognitive function (assessed at baseline and 6 and
12 months ater randomisation) in 185 elderly (>65 years
old) patients with vascular disease. Patients were randomly
allocated to a placebo condition or one of seven difer-
ent treatment conditions. Treatments were (1) B9 (2.5mg)
plus vitamin B12 (0.5mg), (2) vitamin B6 (25mg), and (3)
ribolavin B2 (25mg). Seven treatment comparisons were
undertaken, comprising the three treatment conditions alone
(i.e., 1, 2, and 3) and in combination with each other (i.e.,
1+2, 1+3, 2+3, and 1+2+3). he results suggested that B9 with
B12 could decrease Hcy level but had no efect on cognitive
function.
Other studies have combined intake of B vitamins with
other vitamins that are not from the B vitamin group. In a
large study, over a long treatment period, Clarke et al. [33]
utilised a placebo-controlled trial to investigate the efects
of aspirin (81mg), vitamin B (B9 at 2mg; B12 at 1mg), and
vitamins C and E (200mg and 500mg) ingested daily for
12 weeks on cognitive function (measured by MMSE and
the cognitive part of the Alzheimer’s Disease Assessment
Scale, ADAS-Cog). One hundred and forty-nine participants
(median age = 75 years, medianMMSE = 21, andmedianHcy
= 12.4 �mol/L−1) were randomly allocated to treatment and
placebo arms (6 diferent groups), with 142 of these individ-
uals returning for followup. At baseline (� = 149), data were
split by age (<75 and >75 years old) and severity of cognitive
impairment (interquartile split). Results revealed a negative
correlation between cognitive function and Hcy levels and a
positive association between B9 and cognitive function but
no association between B12 and cognitive function (these
associations remained ater adjustment for age). Ater 12
weeks supplementation with vitamin B (B9 at 2mg, B12 at
1mg), results revealed signiicant increases in B9 and B12 and
signiicant decreases in Hcy. However, there was no efect
on cognitive function. Lewerin et al. [34] utilised a placebo-
controlled trial to investigate the efect of 4 months of
treatment (0.5mg B12, 0.8mg B9 acid, and 3mg B6) on nine
cognitive tasks (digit span forward and backward, identical
forms, visual reproduction, synonyms, block design, digit
symbol,hurstone’s picturememory, and inductive reasoning
task) and ive indices ofmovement (movement time, postural
phase, locomotor phase, manual phase, and simultaneity
index) in 209 community-dwelling elderly volunteers (mean
age 75.41 years, mean tHcy = 16.95 �mol/L, and MMSE was
not completed). At baseline, tHcy and MMA correlated with
cognitive function andmovement; however, B9 andB12 levels
did not. Four months of treatment had no efect on cognitive
function, but did decrease tHcy and MMA levels.
Eussen et al. [35] implemented a placebo-controlled,
between-subjects design to investigate the efect of a 24 week
dietary supplementation period on cognitive function in
elderly (>70 years old) participants with mild vitamin B12
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deiciency (deined as B12 concentration between 100 and
200 pmol/L, or between 200 and 300 pmol/L with concomi-
tant high MMA levels and low creatinine concentrations).
Treatments consisted of (1) B12 (1mg daily, � = 54), (2)
B12 + B9 (1mg + 0.4mg � = 51), and (3) placebo (� =
57). Results demonstrated no efect of either treatment on
cognitive function.
Over a longer treatment period and using larger doses,
Aisen et al. [36] utilised a placebo-controlled-between-
subjects design to investigate the efect of B vitamin sup-
plementation (5mg B9, 25mg B6, and 1mg B12 daily)
for 18 months on cognitive decline in those with mild to
moderate AD (mean age 76 years withMMSE between 14 and
26). Two hundred and two participants received the active
treatment and 138 received the placebo. Results revealed
no beneicial efect of treatment. Similar conclusions were
made by McMahon et al. [37] who investigated the efects
of a 2-year daily treatment regimen (1mg of B9, 0.5mg of
B12, and 10mg of B6) on Hcy and verbal and nonverbal
cognitive function in participants aged 65 years and older
with a baseline Hcy level of at least 13�mol/L. Results
revealed reduction in Hcy following treatment at 6, 12, 18,
and 24 months ater randomisation; however, there was no
efect on cognitive function. Smith et al. [38] implemented
another study over a 24-month period to investigate whether
24-month supplementation with high doses of B vitamins
(B9 0.8mg/d, B12 0.5mg/d, and B6 20mg/d) resulted in
slowing the rate of cerebral atrophy in elderly (>70 years
old) participants withMCI in comparison to placebo. Results
revealed that treatment preceded reduction in tHcy and a
30% reduction in the rate of atrophy, which increased to 53%
reduction in those who had shown the greatest baseline levels
of tHcy (>13 �mol/L). here was no efect of treatment on
those with the lowest baseline levels of tHcy (<9.5 �mol/L).
he authors do not report any data relating to cognitive
performance. In one of the longest treatment studies, Kang
et al. [39] utilised a placebo-controlled design to investigate
the efects of B vitamin supplementation (comprising 2.5mg
B9, 1mg of B12, and 50mg of B6) in two thousand and
nine elderly (mean age 72 years) women with cardiovascular
disease and CVD risk factors (1002 allocated to treatment
group) over a ive-and-half-year period using a telephone
cognitive battery measuring (1) general cognition (Telephone
Interview of Cognitive Status (TICS)), (2) verbal memory
(delayed recall of the TICS 10-word list and the immediate
and delayed recalls of the East Boston Memory Test), and (3)
category luency (asked to name as many animals as possible
in 1 minute). Results revealed no efect of treatment.
10. Conclusions
As summarised in this paper, there appears to be some
robust epidemiological evidence linking B vitamin status and
Hcy with cognitive decline; however, there is still debate
about which marker is the best predictor, and there are a
number of unresolved issues around vulnerability. Despite
this promising link, the empirical evidence that has been
put forward in the literature relating to the potential of
vitamin therapy has proven very disappointing. However,
once again there are fundamental questions that need to be
considered further. It is clear from these and other indings
reported in this paper (together with inconsistencies that
have been highlighted) that further research is warranted in
this domain.
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